ISO 13485 and the FDA QMSR (21 CFR 820): the requirements compared
Since 2 February 2026, the FDA’s quality management system regulation (QMSR) has required makers of finished medical devices to document a quality management system. That system must comply with the applicable requirements of ISO 13485:2016. The rule, Part 820 of Title 21, incorporates the standard by reference, covers devices made in or imported into the US, and adds requirements of its own.
This guide quotes each of those additions from the official text, with what to do and the evidence to keep. It then compares the rules in the EU and Great Britain. Both tell the bodies that audit a quality management system to presume that one built to ISO 13485 meets the requirements the standard covers. So one system can serve the US, the EU and the UK, with each market’s own additions.
The QMSR and ISO 13485: the differences in brief
- Part 820 makes the requirements of the standard’s 2016 edition binding in the US.
- The FDA adds its own requirements on unique device identification, device tracking, complaint reports, and corrections and removals.
- It sets which devices need design controls and extends the standard’s implant traceability clause to devices that support or sustain life. It also adds detail to complaint and servicing records and to labelling and packaging checks.
- US definitions replace some of the standard’s, among them device, labelling and manufacturer.
- Since 2 February 2026, investigators may inspect management review, internal audit and supplier audit reports.
- An ISO 13485 certificate does not exempt a maker from inspection in the US, and the agency issues no such certificate.
- In the EU and Great Britain, the standard is voluntary.
What changed when the QMSR took effect on 2 February 2026
The FDA published the final rule on 2 February 2024 and gave makers two years to prepare:
This rule is effective February 2, 2026.
The rule renamed Part 820 the Quality Management System Regulation. It replaced the Quality System regulation (the QSR), which the FDA’s QMSR page dates to 1 June 1997, and made these changes.
- The standard became part of the rule. Section 820.7 incorporates ISO 13485:2016, the third edition, dated 1 March 2016 (820.7(b)), and Clause 3 of ISO 9000:2015 for its terms. The final rule gives the incorporated standard the same force as text printed in the regulation itself.
- Most of the old sections went. Part 820 now runs from 820.1 to 820.45: scope, definitions, the incorporation and the core requirement in Subpart A, and records, labelling and packaging in Subpart B. The rule removed Subparts C to O.
- The old record names went. Part 820 no longer names the device master record (old 820.181), the design history file, the device history record (old 820.184) or the quality system record (old 820.186). The final rule says the content of the first three now belongs largely in the medical device file (Clause 4.2.3), the design and development file (Clause 7.3.10) and the record for each device or batch (Clause 7.5.1).
- Risk management is explicit. The agency’s QMSR page says the incorporation “now specifically requires risk management”.
- Inspections follow a new programme. The same page says: “On February 2, 2026, the FDA stopped using the Quality System Inspection Technique (QSIT) for device inspections and began utilizing the inspection process described in the updated Inspection of Medical Device Manufacturers Compliance Program: 7382.850.”
- Investigators may read audit and review reports. The old rule kept management review, quality audit and supplier audit reports out of inspections, in 820.180(c). The agency’s questions page now says: “The QMSR gives the FDA the authority to inspect management review, quality audits, and supplier audit reports. The exceptions that existed in the QS regulation at § 820.180(c) are not maintained in the QMSR.” Investigators may also review records made before 2 February 2026.
- A certificate does not replace an inspection. The questions page also says: “The FDA will not require certificates of conformance to ISO 13485 and will not issue certificates of conformance to ISO 13485. A certificate of conformance to ISO 13485 will not exempt a manufacturer from an FDA inspection.”
What to do. Compare your quality manual and procedures with the standard and with the additions listed below, and keep the comparison. For records made before the change, the agency’s questions page says: “A manufacturer may find it useful to complete some type of comparative analysis to demonstrate documents and records created prior to the QMSR effective date meet the QMSR requirements.” Keep management review, internal audit and supplier audit reports ready for an investigator.
Evidence to keep. The dated comparison of your system with ISO 13485:2016 and Part 820; the management review, internal audit and supplier audit reports.
Where the old Part 820 sections went
The regulation’s text and the final rule’s explanations name these moves.
| Before 2 February 2026 | From 2 February 2026 |
|---|---|
| 820.30, design controls | ISO 13485 Clause 7.3 and its subclauses, for the same devices as before (820.10(c)) |
| The 820.30 requirement for a reviewer with no direct responsibility for the design stage under review | No explicit requirement; Clause 7.3.5 sets who takes part in a design review |
| 820.30(g), where the old rule addressed risk management | Risk management through the standard’s clauses, for example 4.1, 7.1, 7.3, 7.4, 7.5, 7.6 and 8.2 |
| 820.65, traceability | Clause 7.5.9, with 820.10(d) for devices that support or sustain life |
| 820.198, complaint files | Clause 8.2.2, with 820.35(a); reports to the FDA under 820.10(b)(3) |
| 820.200, servicing | Clause 7.5.4, with 820.35(b) |
| 820.120 and 820.130, device labeling and device packaging | Clause 7.5.1, with 820.45 |
| 820.150, storage | Clause 7.5.11 |
| 820.20(b)(2), on resources and trained personnel, and 820.75(b)(1), on qualified staff for validated processes | Clause 6.2 |
| 820.100(a)(6) and (7), on sharing quality problems and sending them to management review | Clauses 8.2.2, 8.5.2 and 8.3.1 |
Who must follow the QMSR
Any manufacturers engaged in the design, manufacture, packaging, labeling, storage, installation, or servicing of a finished device must establish and maintain a quality management system that is appropriate for its specific device(s).
- Makers in and outside the US. Part 820 covers finished devices for human use made in the US and devices “imported or offered for import into the United States” (820.1(a)(1)). A maker outside the US that sells into the US must follow it.
- Who counts as a manufacturer. The definition includes firms that sterilise devices under contract, install, relabel, remanufacture or repack them, or develop their specifications. It also covers the initial distributors of foreign makers that do these things (820.3(b)).
- Accessories count. The agency’s QMSR page says: “A manufacturer of accessories is subject to the QMSR.”
- Makers that do only some of the work. A maker that carries out only some of these operations “need only comply with those requirements applicable to the operations in which it is engaged” (820.1(a)). The final rule lets it document the requirements that do not apply to it.
- Who is outside it. Makers of components or parts of finished devices are outside Part 820, though the rule encourages them to consider its provisions (820.1(a)(2)). So are makers of blood and blood components for transfusion or further manufacturing (820.1(a)(3)). Human cells, tissues, and cellular and tissue-based products regulated as devices are inside it (820.1(a)(4)).
- Devices exempt from current good manufacturing practice (CGMP). Some classification regulations exempt a device from these requirements. The FDA’s QMSR page adds: “Exemption from the CGMP requirements does not exempt manufacturers of finished devices from keeping complaint files or from general requirements concerning records required by 21 CFR 820.35.”
- Exemptions and variances. A maker may petition for an exemption or a variance from a requirement (820.1(d)).
What to do. List the operations you carry out on finished devices (design, manufacture, packaging, labelling, storage, installation, servicing) and scope the quality management system to them. Record any requirement you mark as not applicable, with the reason.
Evidence to keep. The scope statement in the quality manual, naming the devices and operations it covers and each exclusion with its reason.
What the QMSR adds to ISO 13485, with what to do and the evidence to keep
Section 820.10(a) sets the core requirement:
Document a quality management system that complies with the applicable requirements of ISO 13485 (incorporated by reference, see § 820.7) and other applicable requirements of this part
The final rule says that “all sections” of the standard “apply to device manufacturers”. Part 820 itself narrows that for each maker: a maker that carries out only some operations follows the requirements for those operations (820.1(a)), and design controls apply only to the devices that 820.10(c) names. Where a clause and US law conflict, US law controls:
to the extent that any clauses of ISO 13485 (incorporated by reference, see § 820.7) conflict with any provisions of the Federal Food, Drug, and Cosmetic Act and/or its other implementing regulations, the Federal Food, Drug, and Cosmetic Act and/or its other implementing regulations will control.
Section 820.10(b) names other US rules a maker must follow “to fully comply with the listed ISO 13485 Clause”. The final rule says the list is incomplete: “the list is not intended to be comprehensive. Regulated manufacturers are responsible for identifying and meeting all applicable requirements, even if such requirements are not specifically called out in § 820.10.”
1. US definitions replace some of the standard’s
All definitions in section 201 of the Federal Food, Drug, and Cosmetic Act shall apply to the regulation of quality management systems under this part and shall supersede the correlating terms and definitions in ISO 13485 (e.g., the definitions of device and labeling in section 201(h) and (m) of the Federal Food, Drug, and Cosmetic Act apply to this part and supersede the definitions for the correlating terms in ISO 13485 (labelling and medical device)).
The same paragraph gives US meanings to more of the standard’s terms. “Organization” means the manufacturer. An “implantable medical device” means an “implant” as 21 CFR 860.3 defines it: “a device that is placed into a surgically or naturally formed cavity of the human body”, which counts as an implant only “if it is intended to remain implanted continuously for a period of 30 days or more, unless the Commissioner determines otherwise to protect human health.” “Safety and performance” in Clause 0.1 means safety and effectiveness, and the phrase “does not relieve a manufacturer from any obligation to implement controls or other measures that provide reasonable assurance of safety and effectiveness”. Section 820.3(a) adds terms that the standards either do not use or do not define, among them finished device, component and remanufacturer.
What to do. Where your quality manual and procedures define terms, add these US meanings for devices sold in the US.
Evidence to keep. A definitions section that cites 21 CFR 820.3 and uses those meanings.
2. Unique device identification under Part 830
For Clause 7.5.8 in ISO 13485, Identification, the manufacturer must document a system to assign unique device identification to the medical device in accordance with the requirements of part 830 of this chapter.
Under 830.20(a), a unique device identifier (UDI) must “Be issued under a system operated by FDA or an FDA-accredited issuing agency”. Part 820 also requires the identifier on record: “the UDI must be recorded for each medical device or batch of medical devices” (820.35(c)). The final rule says the QMSR does not require identifiers for devices still in development, “because the provisions in part 830 apply to a device in commercial distribution”.
What to do. Write down how you assign a UDI to each device that must carry one, through the FDA’s system or an FDA-accredited issuing agency. Record the identifier for each device or batch.
Evidence to keep. The identification procedure; the device or batch records that carry each identifier.
3. Device tracking under Part 821, where the FDA has ordered it
For Clause 7.5.9.1, section 820.10(b)(2) says “the manufacturer must document procedures for traceability in accordance with the requirements of part 821 of this chapter, if applicable.” Part 821 applies when the agency orders a maker to track a class II or class III device (821.1(a)). The final rule adds: “FDA does not consider the reference to part 821 to create a general requirement that an organization’s traceability procedures adhere to the requirements of part 821.”
What to do. Check whether you hold a tracking order for any device. If you do, write the Part 821 tracking procedures into your quality management system.
Evidence to keep. Any tracking order; the tracking procedures and records.
4. Reporting complaints to the FDA under Part 803
For Clause 8.2.3 in ISO 13485, Reporting to regulatory authorities, the manufacturer must notify FDA of complaints that meet the reporting criteria of part 803 of this chapter.
Part 803 sets the criteria and the usual deadline for a maker:
If you are a manufacturer, you must report to us the information required by § 803.52 in accordance with the requirements of § 803.12(a), no later than 30 calendar days after the day that you receive or otherwise become aware of information, from any source, that reasonably suggests that a device that you market: (1) May have caused or contributed to a death or serious injury or (2) Has malfunctioned and this device or a similar device that you market would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur.
It also sets other deadlines. Under 803.53, a 5-day report is due “no later than 5 work days after the day that you become aware” that a reportable event “necessitates remedial action to prevent an unreasonable risk of substantial harm to the public health”, or that the agency has asked in writing for 5-day reports. Under 803.56, information you did not have for the first report goes in a supplemental report “within 30 calendar days of the day that you receive this information”.
What to do. Add a step to complaint handling that checks each complaint against these criteria and sends the report Part 803 requires: within 30 calendar days of the day you become aware, within 5 work days in the cases 803.53 names, and a supplemental report within 30 calendar days of receiving new information.
Evidence to keep. The reporting decision in each complaint record; each report, 5-day report and supplemental report, with the date you filed it.
5. Corrections and removals under Part 806
For Clauses 7.2.3, 8.2.3, and 8.3.3, advisory notices shall be handled in accordance with the requirements of part 806 of this chapter.
Part 806 requires a written report of a correction or removal that a maker starts “(1) To reduce a risk to health posed by the device; or (2) To remedy a violation of the act caused by the device which may present a risk to health” (806.10(a)). The same paragraph sets exceptions: “unless the information has already been provided as set forth in paragraph (f) of this section or the corrective or removal action is exempt from the reporting requirements under § 806.1(b).” Paragraph (f) covers a correction or removal already reported under Part 803 or Part 1004. Section 806.1(b) exempts actions that improve a device without reducing a risk to health or remedying a violation, market withdrawals, routine servicing and stock recoveries. The deadline:
The manufacturer or importer shall submit any report required by paragraph (a) of this section within 10-working days of initiating such correction or removal.
A maker keeps a record of each correction or removal that Part 806 does not require it to report, with the justification for not reporting it (806.20).
What to do. Run every correction or removal through a Part 806 check. Report each one you start to reduce a risk to health, or to remedy a violation that may present one, within 10 working days of starting it, unless you have already reported it under Part 803 or Part 1004 or it falls under an exemption in 806.1(b). Record the others, with the reason you did not report them.
Evidence to keep. Each Part 806 report; the records and justifications for corrections and removals you did not report.
6. Design controls for class II, class III and some class I devices
Manufacturers of class II, class III, and those class I devices listed in paragraph (c)(1) of this section and table 1 to paragraph (c)(2) of this section must comply with the requirements in Design and Development, Clause 7.3 and its Subclauses in ISO 13485.
The class I devices it lists are “Devices automated with computer software” and these named types: tracheobronchial suction catheters (868.6810), non-powdered surgeon’s gloves (878.4460), protective restraints (880.6760), manual radionuclide applicator systems (892.5650) and radionuclide teletherapy sources (892.5740). The final rule keeps the device scope of the old 820.30(a). Devices that a maker builds under an investigational device exemption “are not exempt from design and development requirements under 21 CFR 820.10(c) of the QMSR”, the agency’s QMSR page says.
What to do. Check each device’s class. Apply Clause 7.3 to class II and III devices, to class I devices that run on software and to the named types. For other class I devices, document the exclusion and your justification for it.
Evidence to keep. For each device in scope, the design and development plan and the design and development file (Clause 7.3.10); for each exclusion, the written justification.
7. Traceability for devices that support or sustain life
Manufacturers of devices that support or sustain life, the failure of which to perform when properly used in accordance with instructions for use provided in the labeling can be reasonably expected to result in a significant injury, must comply with the requirements in Traceability for Implantable Devices, Clause 7.5.9.2 in ISO 13485, in addition to all other applicable requirements in this part, as appropriate.
The final rule takes the meaning of the phrase from 21 CFR 860.3, which defines a life-supporting or life-sustaining device as “a device that is essential to, or that yields information that is essential to, the restoration or continuation of a bodily function important to the continuation of human life.”
What to do. List the devices that meet that definition and apply Clause 7.5.9.2 to them, as the standard applies it to implants.
Evidence to keep. The list of devices in scope; the traceability records Clause 7.5.9.2 calls for.
8. What complaint and servicing records must hold
In addition to the requirements of Clause 4.2.5 in ISO 13485 (incorporated by reference, see § 820.7), Control of Records, the manufacturer must include the following information in certain records:
- Complaints (820.35(a)). A maker keeps records of the review, evaluation and investigation of “any complaints involving the possible failure of a device, labeling, or packaging to meet any of its specifications”. When it skips an investigation because it already investigated a similar complaint, it records the justification. A fuller record applies to these complaints: those that Part 803 requires the maker to report, those the maker decides it must investigate, and those it investigated without having to. That record holds:
- the device’s name;
- the date received;
- any UDI or universal product code, and any other identification;
- the complainant’s name, address and phone number;
- the nature and details of the complaint;
- any correction or corrective action;
- any reply to the complainant.
- Servicing (820.35(b)). For servicing under Clause 7.5.4, the record holds at least:
- the device’s name;
- any UDI or universal product code, and any other identification;
- the date of service;
- who serviced it;
- the service performed;
- any test and inspection data.
- Identifiers (820.35(c)). The UDI for each device or batch.
- Confidential records (820.35(d)). “Records deemed confidential by the manufacturer may be marked to aid FDA in determining whether information may be disclosed under the public information regulation in part 20 of this chapter.”
What to do. Add every listed item to your complaint and servicing record forms, and add a field for the justification when you skip an investigation.
Evidence to keep. Complaint and servicing records that carry every listed item.
9. Labelling and packaging checks
In addition to the requirements of Clause 7.5.1 of ISO 13485 (incorporated by reference, see § 820.7), Control of production and service provision, each manufacturer must document and maintain procedures that provide a detailed description of the activities to ensure the integrity, inspection, storage, and operations for labeling and packaging, during the customary conditions of processing, storage, handling, distribution, and, as appropriate, use of the device.
Before release or storage, a maker examines labelling and packaging for accuracy, including the UDI or universal product code, the expiration date, storage instructions, handling instructions and any additional processing instructions (820.45(a)). It documents the release of labelling for use (820.45(b)). It runs labelling and packaging operations to prevent mix-ups, inspects labelling and packaging before use, and documents the results (820.45(c)).
What to do. Write the labelling and packaging procedure, with the accuracy check before release or storage and the inspection before use.
Evidence to keep. The procedure; a record of each labelling release; the inspection results.
What a missed requirement means under US law
The failure to comply with any applicable requirement in this part renders a device adulterated under section 501(h) of the Federal Food, Drug, and Cosmetic Act. Such a device, as well as any person responsible for the failure to comply, is subject to regulatory action.
For a maker outside the US, the same failure can lead the US to refuse its devices entry:
A device that is imported or offered for import into the United States is subject to refusal of admission to the United States under section 801(a) of the Federal Food, Drug, and Cosmetic Act if, among other things, it appears to be adulterated as set forth in the Federal Food, Drug, and Cosmetic Act and its implementing regulations.
How the EU and Great Britain rules compare with the QMSR
In the US, the requirements of ISO 13485 are law. The EU and Great Britain each set their own quality management system requirements in law, and the standard gives a maker a voluntary way to show it meets them.
The EU: Article 10(9) and Annex IX of the Medical Device Regulation
The EU Medical Device Regulation, Regulation (EU) 2017/745, requires a quality management system from every maker, whatever the device’s class:
Manufacturers of devices, other than investigational devices, shall establish, document, implement, maintain, keep up to date and continually improve a quality management system that shall ensure compliance with this Regulation in the most effective manner and in a manner that is proportionate to the risk class and the type of device.
The same paragraph says the system “shall address at least the following aspects”:
- (a) a strategy for regulatory compliance, including compliance with conformity assessment procedures and procedures for management of modifications to the devices covered by the system;
- (b) identification of applicable general safety and performance requirements and exploration of options to address those requirements;
- (c) responsibility of the management;
- (d) resource management, including selection and control of suppliers and sub-contractors;
- (e) risk management as set out in in [sic] Section 3 of Annex I;
- (f) clinical evaluation in accordance with Article 61 and Annex XIV, including PMCF;
- (g) product realisation, including planning, design, development, production and service provision;
- (h) verification of the UDI assignments made in accordance with Article 27(3) to all relevant devices and ensuring consistency and validity of information provided in accordance with Article 29;
- (i) setting-up, implementation and maintenance of a post-market surveillance system, in accordance with Article 83;
- (j) handling communication with competent authorities, notified bodies, other economic operators, customers and/or other stakeholders;
- (k) processes for reporting of serious incidents and field safety corrective actions in the context of vigilance;
- (l) management of corrective and preventive actions and verification of their effectiveness;
- (m) processes for monitoring and measurement of output, data analysis and product improvement.
Under Article 52, class IIa, IIb and III devices go through a notified body, and the quality management system route in Annex IX is open to each of them. For class I devices that are sterile, have a measuring function or are reusable surgical instruments, a notified body checks only those aspects. Other class I makers declare conformity themselves.
Under Annex IX, the notified body audits the system before it certifies it, then keeps auditing it:
If the quality management system conforms to the relevant provisions of this Regulation, the notified body shall issue an EU quality management system certificate.
Notified bodies shall periodically, at least once every 12 months, carry out appropriate audits and assessments to make sure that the manufacturer in question applies the approved quality management system and the post-market surveillance plan.
The notified body also makes unannounced audits “at least once every five years” (Section 3.4).
The European Commission lists EN ISO 13485:2016, with its corrigendum AC:2018 and its amendment A11:2021, among the harmonised standards for the regulation (Implementing Decision (EU) 2021/1182). Article 8(1) presumes that a device in conformity with a harmonised standard meets the requirements the standard covers, and applies the same presumption to quality management systems. Annex IX tells the auditor the same thing about harmonised standards and the EU’s common specifications (CS):
The notified body shall assume that a quality management system which satisfies the relevant harmonised standards or CS conforms to the requirements covered by those standards or CS, unless it duly substantiates not doing so.
Great Britain: the Medical Devices Regulations 2002
The MHRA’s guidance, Regulating medical devices in the UK, says: “Great Britain is England, Wales and Scotland.” Northern Ireland follows the EU rules above. The same guidance says the EU MDR’s requirements “have applied in Northern Ireland since 26 May 2021”.
For general medical devices, regulation 13 of the Medical Devices Regulations 2002 sets the routes to the UKCA marking. Class IIa, IIb and III devices can each take the route in Annex II of Directive 93/42/EEC, as Great Britain modifies it: an approved body’s audit of the maker’s full quality assurance system. The other routes pair a declaration or a type examination with checks under Annexes IV to VI. For class I devices, the maker declares conformity itself, and an approved body checks only the sterility or measuring parts, where a device has them. Annex II, as it applies in Great Britain, sets the requirement and the presumption:
Application of the quality system must ensure that the products conform to the provisions of the Regulations which apply to them at every stage, from design to final inspection.
The approved body must audit the quality system to determine whether it meets the requirements referred to in Section 3.2. It must presume that quality systems which implement the relevant designated standards conform to these requirements.
The MHRA’s guidance on conformity assessment and the UKCA mark explains the designated standards: “If you comply with these designated standards you will conform with the relevant parts of the directive that are covered by these standards. This includes standards such as ISO 13485 covering quality management systems for medical device manufacturers”. It adds: “The use of standards is not mandatory”.
Great Britain also accepts devices CE marked under the EU regulation. Regulation 19C treats a device that meets the EU regulation’s requirements as meeting several of the GB requirements, until this date:
Subject to paragraph (3), regulations 19C, 44ZA and 44ZB cease to have effect at 23:59 on 30 June 2030.
On 21 October 2026, the government’s response to its consultation said it “intends to proceed with legislative changes to indefinitely recognise CE marked medical devices certified under EU MDR and EU IVDR”. Until a change becomes law, the end date in the regulations stays 30 June 2030. Makers of CE marked devices still have duties in Great Britain. The same response says: “Manufacturers of CE marked devices placed on the Great Britain market will continue to be required to comply with certain domestic requirements, including appointment of a UK responsible person, MHRA registration, and post-market surveillance (PMS) obligations.”
Who audits the quality management system, and against what
| US | EU | Great Britain | |
|---|---|---|---|
| The rule | 21 CFR 820.10 | Regulation (EU) 2017/745, Article 10(9) | Medical Devices Regulations 2002, regulation 13, with Annex II, V or VI of Directive 93/42/EEC as modified |
| ISO 13485’s status | Its requirements are part of the rule (820.7) | Harmonised standard, EN ISO 13485:2016 with A11:2021; voluntary | Designated standard; voluntary |
| Who checks the system | FDA investigators, on dates the agency sets by risk factors (questions page, question 13) | A notified body, for class IIa, IIb and III devices and some class I aspects | An approved body, for class IIa, IIb and III devices and the sterility or measuring parts of class I |
| What the maker receives | No certificate | An EU quality management system certificate | A certificate from the approved body |
What to do. If you sell in the EU, check your system against each aspect in Article 10(9). If you sell in Great Britain under the UKCA marking, check it against Section 3.2 of Annex II as Great Britain applies it. If a notified body certifies your system, plan for its yearly surveillance audits and its unannounced audits.
Evidence to keep. A table that maps each Article 10(9) aspect and each GB requirement to the procedure that meets it; certificates and audit reports.
How one ISO 13485 system can serve the US, EU and UK markets
The FDA gave this reason for the change:
registered manufacturers in many other jurisdictions and domestic manufacturers that export devices must comply with ISO 13485, which is substantially similar to the QS regulation. As a result, there is redundant effort for some manufacturers in complying with both the QS regulation and ISO 13485.
It expects makers to run internal audits and management reviews “based on aligned requirements as opposed to auditing and assessing separately to comply with the requirements of the previous QS regulation and ISO 13485 individually”.
The final rule also describes the Medical Device Single Audit Program (MDSAP): “MDSAP is a certification program that allows for a single QMS audit based on ISO 13485 in addition to other applicable FDA device regulatory requirements, which FDA may accept in lieu of routine surveillance inspections conducted by FDA investigators.” The agency’s questions page says MDSAP “is a voluntary third-party audit program and will still be available to manufacturers who choose to participate.”
What to do. Build the system once, to ISO 13485:2016, then keep one list of each market’s additions, each mapped to the procedure that meets it: Part 820’s requirements for the US; the Article 10(9) aspects for the EU; and, for Great Britain, Annex II with the UK responsible person, MHRA registration and post-market surveillance duties.
Evidence to keep. That list, kept current, with the source of each requirement.
Questions about the standard and the US regulation
What is ISO 13485?
It is the international standard that sets quality management system requirements for medical device makers, for regulatory purposes. Its current edition is ISO 13485:2016, the third, dated 1 March 2016. The FDA’s 2022 proposal lists the titles of clauses 4 to 8 as quality management system, management responsibility, resource management, product realization, and measurement, analysis and improvement.
Is ISO 13485:2016 still the current version?
Yes. ISO’s page says: “This publication was last reviewed and confirmed in 2025. Therefore this version remains current.” Part 820 names the 2016 edition, so a later edition would apply in the US only after an amendment to the rule. The agency’s questions page says: “The FDA will evaluate any future revisions to this standard to determine the impact of any changes and whether the QMSR should be amended.”
Does the FDA require ISO 13485 certification?
No. The agency’s questions page says it will neither require nor issue certificates of conformance to the standard, and that a certificate will not exempt a maker from inspection (question 13). In the EU and Great Britain, notified bodies and approved bodies issue quality management system certificates.
What is the difference between the QSR and the QMSR?
The QSR is the Quality System regulation, the FDA’s rule for device quality systems until 2 February 2026. The QMSR replaced it on that date and incorporates ISO 13485:2016. The final rule finds the standard “substantially similar” to the old rule when taken as a whole. In practice, the old record names went, investigators may inspect management review and audit reports, inspections follow a new programme, and the FDA’s own additions apply.
Where did 21 CFR 820.30 design controls go?
They moved to ISO 13485 Clause 7.3 and its subclauses. Section 820.10(c) applies Clause 7.3 to the same devices the old 820.30(a) covered: class II and III devices, and the class I devices it lists, including devices automated with computer software.
What is EN ISO 13485?
It is the European standard that adopts the international standard’s 2016 edition. The European Commission lists it, with its corrigendum AC:2018 and amendment A11:2021, among the harmonised standards for the EU Medical Device Regulation. Under Article 8(1), the regulation presumes that a quality management system that conforms to it meets the requirements it covers.
Can I read ISO 13485 for free?
Yes, read only. The final rule says the American National Standards Institute’s portal for incorporated standards “will give the user access to a read-only version of ISO 13485 and Clause 3 of ISO 9000, at no cost to the user.” ISO sells copies (21 CFR 820.7), and its page sends buyers in the United Kingdom to the BSI store.
More guides
- 21 CFR Part 11 · EU Annex 1121 CFR Part 11 compliance: the requirements and EU Annex 11 comparedRead the guide
- 21 CFR Part 806 · EU MDR · UK MDR 2002Field safety corrective action and medical device recalls: the US, EU and UK rulesRead the guide
- 21 CFR Part 860 · EU MDR Annex VIIIMedical device classification: class 1, 2 and 3 under the FDA, EU and MHRA rulesRead the guide
Sources
United States
- 21 CFR Part 820, Quality Management System Regulation, eCFR, up to date as of 16 November 2026: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-820
- 21 CFR 803.50: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-803/subpart-E/section-803.50
- 21 CFR 803.53: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-803/subpart-E/section-803.53
- 21 CFR 803.56: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-803/subpart-E/section-803.56
- 21 CFR 806.1: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-806/subpart-A/section-806.1
- 21 CFR 806.10: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-806/subpart-B/section-806.10
- 21 CFR 806.20: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-806/subpart-B/section-806.20
- 21 CFR 821.1: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-821/subpart-A/section-821.1
- 21 CFR 830.20: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-830/subpart-B/section-830.20
- 21 CFR 860.3: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-860/subpart-A/section-860.3
- Federal Register, Medical Devices; Quality System Regulation Amendments, final rule, 89 FR 7496, 2 February 2024: https://www.federalregister.gov/documents/2024/02/02/2024-01709/medical-devices-quality-system-regulation-amendments
- Federal Register, the correction, 89 FR 82945, 15 October 2024: https://www.federalregister.gov/documents/2024/10/15/2024-23701/medical-devices-quality-system-regulation-amendments-correction
- Federal Register, the proposed rule, 87 FR 10119, 23 February 2022: https://www.federalregister.gov/documents/2022/02/23/2022-03227/medical-devices-quality-system-regulation-amendments
- FDA, Quality Management System Regulation (QMSR): https://www.fda.gov/medical-devices/postmarket-requirements-devices/quality-management-system-regulation-qmsr
- FDA, Quality Management System Regulation, Frequently Asked Questions: https://www.fda.gov/medical-devices/quality-management-system-regulation-qmsr/quality-management-system-regulation-frequently-asked-questions
European Union
- Regulation (EU) 2017/745 on medical devices, consolidated text of 9 November 2026, EUR-Lex: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:02017R0745-20261109
- Commission Implementing Decision (EU) 2021/1182 on harmonised standards for medical devices, consolidated text of 17 June 2026, EUR-Lex: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:02021D1182-20260617
Great Britain
- The Medical Devices Regulations 2002 (SI 2002/618), regulations 1ZA, 2(1A), 3A, 13 and 19C, and Schedule 2A, paragraph 13, legislation.gov.uk: https://www.legislation.gov.uk/uksi/2002/618/contents
- Directive 93/42/EEC, Annex II, legislation.gov.uk: https://www.legislation.gov.uk/eudr/1993/42/annex/II
- MHRA, Medical devices: conformity assessment and the UKCA mark: https://www.gov.uk/guidance/medical-devices-conformity-assessment-and-the-ukca-mark
- MHRA, Regulating medical devices in the UK: https://www.gov.uk/guidance/regulating-medical-devices-in-the-uk
- Government response to the targeted consultation on the indefinite recognition of CE marked devices, 21 October 2026: https://www.gov.uk/government/consultations/medical-devices-regulations-targeted-consultation-on-the-indefinite-recognition-of-ce-marked-devices
The standard
- ISO, ISO 13485:2016: https://www.iso.org/standard/59752.html
General information, not legal advice. We read every source above in November 2026 and check them each month; the date at the top of the page shows the last review.